诺和诺德ziltivekimab在ZEUS试验中未减少心血管事件，心脏病学家表示仍将探索抗炎治疗
诺和诺德单克隆抗体ziltivekimab在ZEUS试验中降低了炎症细胞因子IL-6水平，但在病情严重的患者中，相比安慰剂未减少心肌梗死、卒中或死亡；结果在美国心脏协会科学年会公布并同步发表于《新英格兰医学杂志》。因数据监查委员会9月判定不太可能成功，诺和诺德已停止该药另外两项试验HERMES与ATHENA。报道引述心脏病学家观点：尽管该药失败，仍将继续探索抗炎治疗。
#Novo Nordisk
STAT · 医学与生命科学新闻
EMA · News and Safety Reviews精选 内分泌与代谢：Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
原文摘录：Image credit: © Marcos Osorio/Stocksy | stock.adobe.com Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16 October 2026 Six new medicines recommended for approval; another five medicines recommended for … eu All other enquiries please submit your request via the online form Follow us on Bluesky Related medicine information Foundayo Rasonque Yuviwel Fovlussea Neuzafy Kizfizo Kyinsu Talvey Tukysa Tryngolza Yartemlea Mylotarg Truqap Ibrance
关注理由：这条内分泌与代谢资料涉及具体临床问题，研究人群、方法和结局指标可以结合原文进一步查看。